Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa

AIDS Research and Human Retroviruses

Volumn 30, Issue 3, 2014, Pages 289-293

  Ketseoglou, Irene ^a,b   Lukhwareni, Azwidowi ^b   Steegen, Kim ^a   Carmona, Sergio ^a,b   Stevens, Wendy S ^a,b   Papathanasopoulos, Maria A ^a,c  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN C); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; SOUTH AFRICA; VIRAL CLEARANCE; VIRAL TROPISM; VIRUS LOAD; VIRUS MUTATION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; RECEPTORS, HIV; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; TREATMENT FAILURE; VIRAL TROPISM;

EID: 84895549977     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0267     Document Type: Article

References (25)

1. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
2. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
3. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997;184: 621-628.
4. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism and disease. Annu Rev Immunol 1999;17:657-700.
5. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, et al.: Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71:7478-7487.
6. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho E, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
7. Penn ML, Grivel JC, Schramm B, Goldsmith MA, and Margolis L: CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1 infected human lymphoid tissue. Proc Natl Acad Sci USA 1999;96:663-668.
8. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, et al.: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996;70:8355-8360.
9. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997;3:1259-1265.
10. Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, et al.: HIV-1 subtype C syncytium and non-syncytium-inducing phenotype and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999;13:1305-1311.
11. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, and Fenyo M: Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 1999;15:647-653.
12. Ping LH, Nelson JA, Hoffman IF, Schock J, Lamers SL, Goodman M, et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants. J Virol 1999;73:6271-6281.
13. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, and Gadkari DA: Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 2000;271:253-258.
14. Cilliers T, Nhlapo J, Coetzer M, Orlovic D, Ketas T, Olson WC, et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003;77:4449-4456.
15. Connell BJ, Michler K, Capovilla A, Venter VD, Stevens WS, and Papathanasopoulos MA: Emergence of X4 usage among HIV-1 subtype C: Evidence for an evolving epidemic in South Africa. AIDS 2008;22:896-899.
16. Michler K, Connell BJ, Venter VD, Stevens WS, Capovilla A, and Papathanasopoulos MA: Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res Hum Retroviruses 2008;24:743-751.
17. Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, et al.: European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11:394-407.
18. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, et al.: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in Kwa Zulu Natal, South Africa. Clin Infect Dis 2008;46:1589-1597.
19. Singh A, Sunpath H, Green TN, Padayachi N, Hiramen K, Lie Y, et al.: Drug resistance and viral tropism in HIV-1 subtype C-infected patients in Kwa Zulu-Natal, South Africa: Implications for future treatment options. J Acquir Immune Defic Syndr 2011;58:233-240.
20. Hoffmann CJ, Ledwaba J, Li JF, Johnston V, Hunt G, Fielding KL, et al.: Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther 2013;June 10. (Epub ahead of print); DOI: 10.3851/IMP2652.
21. Green TN, Archary M, Gordon ML, Padayachi N, Lie Y, Anton ED, et al.: Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses 2012;28:324-332.
22. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, et al.: Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007;21:F17-F24.
23. Seclén E, Soriano V, Gonzalez MM, Gomez S, Thielen A, and Povedai E: High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J Clin Microbiol 2011;49:3380-3382.
24. Pillai S, Good B, Richman D, and Corbeil J: A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003;19:145-149.
25. Cashin K, Gray LR, Jakobsen MR, Sterjovski J, Churchill MJ, and Gorry PR: CoRSeqv3-c: A novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm. Retrovirology 2013;10:24-34.